Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.61USD
26 May 2017
Change (% chg)

$0.01 (+2.50%)
Prev Close
$0.59
Open
$0.60
Day's High
$0.61
Day's Low
$0.58
Volume
51,203
Avg. Vol
86,252
52-wk High
$2.25
52-wk Low
$0.41

Latest Key Developments (Source: Significant Developments)

Synthetic Biologics receives FDA breakthrough therapy designation for SYN-004
Thursday, 11 May 2017 07:00am EDT 

May 11 (Reuters) - Synthetic Biologics Inc -:SYN-004 (ribaxamase) receives breakthrough therapy designation from U.S. Food and Drug Administration for prevention of clostridium difficile infection.Synthetic Biologics-anticipate requesting type-b multidisciplinary meeting with agency for discussion on development plan, pathway to licensure for ribaxamase.  Full Article

Synthetic Biologics qtrly loss per share $0.02
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Synthetic Biologics Inc :Qtrly loss per share $0.02.  Full Article

Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010
Wednesday, 18 Jan 2017 04:09pm EST 

Synthetic Biologics Inc : Synthetic Biologics confirms key features of pivotal Phase 2b/3 trial of SYN-010 pursuant to consultations with FDA . Synthetic Biologics confirms key features of pivotal phase 2B/3 trial of SYN-010 pursuant to consultations with FDA .Synthetic Biologics Inc says company anticipates initiating this trial by end of Q1 of 2017.  Full Article

Synthetic Biologics announces pricing of public offering of common stock
Tuesday, 15 Nov 2016 09:08am EST 

Synthetic Biologics Inc - : Pricing of offering of 25 million shares of its common stock and warrants to purchase 50 million shares of common stock at $1.00/share .Synthetic biologics announces pricing of public offering of common stock and warrants.  Full Article

Synthetic Biologics posts quarterly loss of 9 cents/share
Tuesday, 1 Nov 2016 06:58am EDT 

Synthetic Biologics Inc : Synthetic biologics inc - qtrly loss per share $0.09 .Synthetic biologics reports third quarter 2016 operational highlights and financial results.  Full Article

Synthetic Biologics awarded research contract from Centers for Disease Control and Prevention (CDC)
Thursday, 6 Oct 2016 06:58am EDT 

Synthetic Biologics Inc : Synthetic Biologics awarded research contract from Centers For Disease Control And Prevention (CDC) for microbiome assessment and intervention to address antibiotic resistance . Funding to support study to determine SYN-004'S ability to prevent emergence of antibiotic-resistance in gut microbiome of subjects .Contract to help CDC assess how selective pressure from IV antibiotics may lead to emergence of antibiotic resistance in gut microbiome.  Full Article

Synthetic Biologics and FBR Capital Markets enter into a sales agreement
Friday, 5 Aug 2016 06:09am EDT 

Synthetic Biologics Inc : On August 5, 2016, co and FBR Capital Markets & Co entered into an at market issuance sales agreement - SEC filing .Pursuant to agreement company may sell up to $40 million of its stock through FBR.  Full Article

Synthetic Biologics reports Q2 2016 operational highlights & financial results
Wednesday, 3 Aug 2016 04:01pm EDT 

Synthetic Biologics Inc : Synthetic Biologics reports second quarter 2016 operational highlights and financial results . Qtrly loss per share $0.10 .Q2 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.  Full Article

Synthetic Biologics releases data from two mid-stage trials on drug for irritable bowel syndrome with constipation
Monday, 23 May 2016 06:50am EDT 

Synthetic Biologics Announces Detailed Data From Two Syn : Syn-010 was well tolerated in both study 1 and study 2 patients . One mild incidence of diarrhea was reported during both studies and identified by investigator as unrelated to syn-010 . Also remain on track to initiate our phase 3 clinical program for syn-010 for treatment of ibs-c later this year .010 phase 2 clinical trials for the treatment of irritable bowel syndrome with constipation (ibs-c).  Full Article

Synthetic Biologics announces positive topline results from second phase 2A clinical trial of SYN-004
Monday, 16 May 2016 07:02am EDT 

Synthetic Biologics : 150 mg dose strength of syn-004 was well tolerated by all participants in this clinical trial . Syn-004 degraded iv ceftriaxone in presence of a proton pump inhibitor in gastrointestinal tract without affecting antibiotic levels . An interim analysis of blinded data performed by an independent data monitoring committee is expected in summer of 2016 .Announces Positive Topline Results From Second Phase 2a Clinical Trial Of Syn-004 for the prevention of c. Difficile infection and antibiotic-associated diarrhea.  Full Article

More From Around the Web

BRIEF-Synthetic Biologics receives FDA breakthrough therapy designation for SYN-004

* SYN-004 (ribaxamase) receives breakthrough therapy designation from U.S. Food and Drug Administration for prevention of clostridium difficile infection